文献速递眼底病与葡萄膜炎

CATT 试验中新生血管性年龄相关性黄斑变性治疗眼非地图样萎缩的发病率与进展

Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

该研究为 CATT 临床试验的事后分析,纳入 1107 例新生血管性年龄相关性黄斑变性(nAMD)患者,评估抗 VEGF 治疗后非地图样萎缩(NGA)的发病率、进展及相关危险因素。结果显示,1、2、5 年 NGA 风险分别为 35%、59%、81%;2 年内出现 NGA 的 389 眼中,1、3、4 年进展为地图样萎缩(GA)的风险分别为 29%、43%、50%。

要点

  • 抗 VEGF 治疗 2 年后超过半数 nAMD 眼发生 NGA,5 年风险达 81%。
  • 基线视力差、新生血管面积大、换药方案及 ARMS2/HTRA1 变异增加 NGA 风险。
  • 2 年内出现 NGA 的眼,后续 4 年约半数进展为 GA。

核心结论

  • 接受抗 VEGF 治疗的 nAMD 眼在 2 年后超过半数发生 NGA,其中约半数在随后 3 年进展为 GA。

研究设计与样本

  • CATT 临床试验的事后队列分析,纳入 1107 例参与者,随机接受雷珠单抗或贝伐珠单抗治疗。

主要发现

  • NGA 风险在 1、2、5 年分别为 35%(391 眼)、59%(246 眼)、81%(122 眼)。
  • 2 年内出现 NGA 的 389 眼中,进展为 GA 的风险在 1、3、4 年分别为 29%、43%、50%。

关键数值与推荐

  • NGA 定义为彩色图像上的色素减退和色素沉着。
  • NGA 危险因素包括:视力 20/200-20/320(aRR 1.74)、新生血管面积>4 盘面积(aRR 1.31)、换药方案(aRR 1.28)、ARMS2 TT 变异(RR 1.53)、HTRA1 AG 变异(RR 1.23)及 AA 变异(RR 1.51)。
  • GA 进展危险因素包括:视力 20/200-20/320(aRR 2.75)、对侧眼视力<20/40(aRR 1.77)、对侧眼 GA(aRR 1.71)、任一眼假性玻璃膜疣(aRR 1.65)。

临床怎么用

  • 对 nAMD 抗 VEGF 治疗患者应长期监测 NGA 及 GA 的发生与进展。
  • 基线视力较差、新生血管面积大、存在 ARMS2/HTRA1 变异者需警惕 NGA 风险。

局限性

  • 本研究为事后分析,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Retinal hypopigmentation and hyperpigmentation are precursors of geographic atrophy (GA). Incidence and progression to GA in eyes treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration (nAMD) have not been investigated. OBJECTIVE: To determine the incidence and progression of non-GA (NGA) and associated risk factors. DESIGN, SETTING, AND PARTICIPANTS: This study is a post hoc analysis of a cohort study within the Comparison of Age-Related Treatments Trials (CATT) clinical trial. Participants were recruited February 20, 2008, through December 9, 2009; released from protocol follow-up and treatment after 2 years; and recalled from March 14, 2014, through March 31, 2015. Data analyses were conducted from January 11, 2019, through November 27, 2019. INTERVENTIONS: Participants were randomized to ranibizumab or bevacizumab for (1) 2 years of monthly or as-needed injections or (2) monthly injections for 1 year and as-needed injections the following year. Participants were treated according to best medical judgement thereafter. MAIN OUTCOMES AND MEASURES: Incidence of nAMD-associated NGA (hypopigmentation and hyperpigmentation in color images) and progression; adjusted risk ratios (aRR) for baseline characteristics. RESULTS: Among 1107 participants, risk of NGA was 35% (391 eyes), 59% (246 eyes), and 81% (122 eyes) at 1, 2, and 5 years, respectively. Risk factors for NGA included worse visual acuity (20/200-20/320: aRR, 1.74 [95% CI, 1.24-2.43], compared with ≤20/40; P = .006), larger neovascularization area (>4 disc areas: aRR, 1.31 [95% CI, 1.01-1.71], compared with ≤1 disc areas; P = .007), switched drug regimen (aRR, 1.28 [95% CI, 1.06-1.54], compared with as-needed injections; P = .02), and single-nucleotide variants Age-Related Maculopathy Susceptibility 2 (ARMS2) (TT variant: relative risk [RR], 1.53 [95% CI, 1.22-1.93]; P = .001) and HtrA Serine Peptidase 1 (HTRA1) (AG variant: RR, 1.23 [95% CI, 1.01-1.48]; AA variant: RR, 1.51 [95% CI, 1.20-1.91]; P = .002). Sub-retinal pigment epithelium thickness was protective (>275 μm: aRR, 0.59 [95% CI, 0.46-0.75], compared with ≤75 μm; P < .001). Among 389 eyes with NGA by 2 years and subsequent color images, risk of progression to GA was 29%, 43%, and 50% at 1, 3, and 4 years, respectively. Risk factors for progression to GA included worse visual acuity (20/200-20/320: aRR, 2.75 [95% CI, 1.54-4.93], compared with ≤20/40; P < .001), worse fellow-eye visual acuity (<20/40: aRR, 1.77 [95% CI, 1.12-2.79], compared with ≥20/40; P = .01), fellow-eye GA (aRR, 1.71 [95% CI, 1.06-2.75]; P = .03), and pseudodrusen in either eye (aRR, 1.65 [95% CI, 1.17-2.34]; P = .005). Subretinal fluid was associated with a decreased risk of progression (aRR, 0.42 [95% CI, 0.28-0.63]; P < .001). CONCLUSIONS AND RELEVANCE: In this study, after 2 years of protocol-guided anti-vascular endothelial growth factor treatment for nAMD, more than half of the eyes in the study developed NGA in the location of nAMD. After 3 additional years of regular care, half of them progressed to GA. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00593450.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Daniel E, Maguire MG, Grunwald JE, et al. Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial. JAMA Ophthalmol. 2020. PMID: 32191267. doi:10.1001/jamaophthalmol.2020.0437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。